| 1 |
Clinical Phase II Development of NT‑101: An Innovative Topical Therapy for wet Age‑Related Macular Degeneration |
| rProtein |
wet AMD |
PEDF pathway (angiogenesis and neuroprotection) |
Phase 2 |
NexThera Co., Ltd. |
RS-2026-25502180 |
|
| 2 |
Clinical Development and Commercialization of NG101: A Gene Therapy for Wet Age-Related Macular Degeneration |
| Gene & Nucleic acids |
wet-AMD |
VEGF |
Phase 2 |
Neuracle Genetics |
RS-2025-02213615 |
|
| 3 |
Future Medicine FM101-Oral Glaucoma Treatment |
| Small molecules |
Glaucoma, Ocular hypertension |
A3AR |
Phase 2 |
Future Medicine Co., Ltd. |
HN22C0520 |
|